Gauging seizure risk

The current paradigm for treatment of epilepsy begins with trials of antiepileptic drugs, followed by evaluation for resective brain surgery in drug-resistant patients. If surgery is not possible or fails to control seizures, some patients benefit from implanted neurostimulation devices. In addition...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2018-11, Vol.91 (21), p.967-973
Hauptverfasser: Baud, Maxime O, Rao, Vikram R
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 973
container_issue 21
container_start_page 967
container_title Neurology
container_volume 91
creator Baud, Maxime O
Rao, Vikram R
description The current paradigm for treatment of epilepsy begins with trials of antiepileptic drugs, followed by evaluation for resective brain surgery in drug-resistant patients. If surgery is not possible or fails to control seizures, some patients benefit from implanted neurostimulation devices. In addition to their therapeutic benefit, some of these devices have diagnostic capability enabling recordings of brain activity with unprecedented chronicity. Two recent studies using different devices for chronic EEG (i.e., over months to years) yielded convergent findings of daily and multiday cycles of brain activity that help explain seizure timing. Knowledge of these patient-specific cycles can be leveraged to gauge and forecast seizure risk, empowering patients to adopt risk-stratified treatment strategies and behavioral modifications. We review evidence that epilepsy is a cyclical disorder, and we argue that implanted monitoring devices should be offered earlier in the treatment paradigm. Chronic EEG would allow pharmacologic treatments tailored to days of high seizure risk—here termed chronotherapy—and would help characterize long timescale seizure dynamics to improve subsequent surgical planning. Coupled with neuromodulation, the proposed approach could improve quality of life for patients and decrease the number ultimately requiring resective surgery. We outline challenges for chronic monitoring and seizure forecasting that demand close collaboration among engineers, neurosurgeons, and neurologists.
doi_str_mv 10.1212/WNL.0000000000006548
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2125307859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2125307859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3568-5014525f81aa2632e6438a8f2d8c13f435ef5f3c8695dc0274ae0389b3493a203</originalsourceid><addsrcrecordid>eNp9kDFPwzAQhS0EoqWwMSLUkSXl7LMTZ0QVFKQKFhBslpue29C0KXaiCn49Ri0IMXDLDfe993SPsTMOAy64uHy-Hw_g16RK6j3W5UqkSYriZZ91AYROUGe6w45CeAWIxyw_ZB0EVCoD3mWnI9vOytWsH6j8aD31fRkWx-zA2SrQyW732NPN9ePwNhk_jO6GV-OkQJXqRAGXSiinubUiRlIqUVvtxFQXHJ1ERU45LHSaq2kBIpOWAHU-QZmjFYA9drH1Xfv6raXQmGUZCqoqu6K6DSa-qRAyrfKIyi1a-DoET86sfbm0_t1wMF99mNiH-dtHlJ3vEtrJkqY_ou8CIqC3wKauGvJhUbUb8mZOtmrm_3t_AqcjaLw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2125307859</pqid></control><display><type>article</type><title>Gauging seizure risk</title><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Baud, Maxime O ; Rao, Vikram R</creator><creatorcontrib>Baud, Maxime O ; Rao, Vikram R</creatorcontrib><description>The current paradigm for treatment of epilepsy begins with trials of antiepileptic drugs, followed by evaluation for resective brain surgery in drug-resistant patients. If surgery is not possible or fails to control seizures, some patients benefit from implanted neurostimulation devices. In addition to their therapeutic benefit, some of these devices have diagnostic capability enabling recordings of brain activity with unprecedented chronicity. Two recent studies using different devices for chronic EEG (i.e., over months to years) yielded convergent findings of daily and multiday cycles of brain activity that help explain seizure timing. Knowledge of these patient-specific cycles can be leveraged to gauge and forecast seizure risk, empowering patients to adopt risk-stratified treatment strategies and behavioral modifications. We review evidence that epilepsy is a cyclical disorder, and we argue that implanted monitoring devices should be offered earlier in the treatment paradigm. Chronic EEG would allow pharmacologic treatments tailored to days of high seizure risk—here termed chronotherapy—and would help characterize long timescale seizure dynamics to improve subsequent surgical planning. Coupled with neuromodulation, the proposed approach could improve quality of life for patients and decrease the number ultimately requiring resective surgery. We outline challenges for chronic monitoring and seizure forecasting that demand close collaboration among engineers, neurosurgeons, and neurologists.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000006548</identifier><identifier>PMID: 30355701</identifier><language>eng</language><publisher>United States: American Academy of Neurology</publisher><ispartof>Neurology, 2018-11, Vol.91 (21), p.967-973</ispartof><rights>2018 American Academy of Neurology</rights><rights>2018 American Academy of Neurology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3568-5014525f81aa2632e6438a8f2d8c13f435ef5f3c8695dc0274ae0389b3493a203</citedby><cites>FETCH-LOGICAL-c3568-5014525f81aa2632e6438a8f2d8c13f435ef5f3c8695dc0274ae0389b3493a203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30355701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baud, Maxime O</creatorcontrib><creatorcontrib>Rao, Vikram R</creatorcontrib><title>Gauging seizure risk</title><title>Neurology</title><addtitle>Neurology</addtitle><description>The current paradigm for treatment of epilepsy begins with trials of antiepileptic drugs, followed by evaluation for resective brain surgery in drug-resistant patients. If surgery is not possible or fails to control seizures, some patients benefit from implanted neurostimulation devices. In addition to their therapeutic benefit, some of these devices have diagnostic capability enabling recordings of brain activity with unprecedented chronicity. Two recent studies using different devices for chronic EEG (i.e., over months to years) yielded convergent findings of daily and multiday cycles of brain activity that help explain seizure timing. Knowledge of these patient-specific cycles can be leveraged to gauge and forecast seizure risk, empowering patients to adopt risk-stratified treatment strategies and behavioral modifications. We review evidence that epilepsy is a cyclical disorder, and we argue that implanted monitoring devices should be offered earlier in the treatment paradigm. Chronic EEG would allow pharmacologic treatments tailored to days of high seizure risk—here termed chronotherapy—and would help characterize long timescale seizure dynamics to improve subsequent surgical planning. Coupled with neuromodulation, the proposed approach could improve quality of life for patients and decrease the number ultimately requiring resective surgery. We outline challenges for chronic monitoring and seizure forecasting that demand close collaboration among engineers, neurosurgeons, and neurologists.</description><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kDFPwzAQhS0EoqWwMSLUkSXl7LMTZ0QVFKQKFhBslpue29C0KXaiCn49Ri0IMXDLDfe993SPsTMOAy64uHy-Hw_g16RK6j3W5UqkSYriZZ91AYROUGe6w45CeAWIxyw_ZB0EVCoD3mWnI9vOytWsH6j8aD31fRkWx-zA2SrQyW732NPN9ePwNhk_jO6GV-OkQJXqRAGXSiinubUiRlIqUVvtxFQXHJ1ERU45LHSaq2kBIpOWAHU-QZmjFYA9drH1Xfv6raXQmGUZCqoqu6K6DSa-qRAyrfKIyi1a-DoET86sfbm0_t1wMF99mNiH-dtHlJ3vEtrJkqY_ou8CIqC3wKauGvJhUbUb8mZOtmrm_3t_AqcjaLw</recordid><startdate>20181120</startdate><enddate>20181120</enddate><creator>Baud, Maxime O</creator><creator>Rao, Vikram R</creator><general>American Academy of Neurology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181120</creationdate><title>Gauging seizure risk</title><author>Baud, Maxime O ; Rao, Vikram R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3568-5014525f81aa2632e6438a8f2d8c13f435ef5f3c8695dc0274ae0389b3493a203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baud, Maxime O</creatorcontrib><creatorcontrib>Rao, Vikram R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baud, Maxime O</au><au>Rao, Vikram R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gauging seizure risk</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2018-11-20</date><risdate>2018</risdate><volume>91</volume><issue>21</issue><spage>967</spage><epage>973</epage><pages>967-973</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>The current paradigm for treatment of epilepsy begins with trials of antiepileptic drugs, followed by evaluation for resective brain surgery in drug-resistant patients. If surgery is not possible or fails to control seizures, some patients benefit from implanted neurostimulation devices. In addition to their therapeutic benefit, some of these devices have diagnostic capability enabling recordings of brain activity with unprecedented chronicity. Two recent studies using different devices for chronic EEG (i.e., over months to years) yielded convergent findings of daily and multiday cycles of brain activity that help explain seizure timing. Knowledge of these patient-specific cycles can be leveraged to gauge and forecast seizure risk, empowering patients to adopt risk-stratified treatment strategies and behavioral modifications. We review evidence that epilepsy is a cyclical disorder, and we argue that implanted monitoring devices should be offered earlier in the treatment paradigm. Chronic EEG would allow pharmacologic treatments tailored to days of high seizure risk—here termed chronotherapy—and would help characterize long timescale seizure dynamics to improve subsequent surgical planning. Coupled with neuromodulation, the proposed approach could improve quality of life for patients and decrease the number ultimately requiring resective surgery. We outline challenges for chronic monitoring and seizure forecasting that demand close collaboration among engineers, neurosurgeons, and neurologists.</abstract><cop>United States</cop><pub>American Academy of Neurology</pub><pmid>30355701</pmid><doi>10.1212/WNL.0000000000006548</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2018-11, Vol.91 (21), p.967-973
issn 0028-3878
1526-632X
language eng
recordid cdi_proquest_miscellaneous_2125307859
source Alma/SFX Local Collection; Journals@Ovid Complete
title Gauging seizure risk
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A50%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gauging%20seizure%20risk&rft.jtitle=Neurology&rft.au=Baud,%20Maxime%20O&rft.date=2018-11-20&rft.volume=91&rft.issue=21&rft.spage=967&rft.epage=973&rft.pages=967-973&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000006548&rft_dat=%3Cproquest_cross%3E2125307859%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2125307859&rft_id=info:pmid/30355701&rfr_iscdi=true